Edesa Biotech (EDSA) Depreciation & Amortization (CF) (2013 - 2025)
Edesa Biotech (EDSA) posted Depreciation & Amortization (CF) of $25460.0 for Q4 2025, down 1.58% sequentially from $25868.0 in Q3 2025, and down 40.94% YoY from $43109.0 in Q4 2024.
Edesa Biotech (EDSA) Depreciation & Amortization (CF) (2013 - 2025) Analysis & Trends
Edesa Biotech has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $25460.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 40.94% year-over-year to $25460.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $101624.0 (down 44.81% YoY) and the FY2025 annual result came in at $119273.0, down 35.89% from the prior year.
- Depreciation & Amortization (CF) declined to $25460.0 in Q4 2025 per EDSA's latest filing, from $25868.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $82999.0 in Q2 2023 and troughed at $24509.0 in Q1 2025.
- A 5-year average of $36119.3 and a median of $29778.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 1024.25% in 2021, down 100.0% in 2021.
- Over 5 years, Depreciation & Amortization (CF) stood at $29752.0 in 2021, then decreased by 8.59% to $27197.0 in 2022, then jumped by 65.57% to $45031.0 in 2023, then declined by 4.27% to $43109.0 in 2024, then sank by 40.94% to $25460.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $25460.0, $25868.0, and $25787.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25,460.00 |
| Dec 31, 2025 | 25,460.00 |
| Sep 30, 2025 | 25,868.00 |
| Sep 30, 2025 | 25,868.00 |
| Jun 30, 2025 | 25,787.00 |
| Jun 30, 2025 | 25,787.00 |
| Mar 31, 2025 | 24,509.00 |
| Mar 31, 2025 | 24,509.00 |
| Dec 31, 2024 | 43,109.00 |
| Dec 31, 2024 | 43,109.00 |
| Sep 30, 2024 | 44,206.00 |
| Sep 30, 2024 | 44,206.00 |
| Jun 30, 2024 | 51,415.00 |
| Jun 30, 2024 | 51,415.00 |
| Mar 31, 2024 | 45,397.00 |
| Mar 31, 2024 | 45,397.00 |
| Dec 31, 2023 | 45,031.00 |
| Dec 31, 2023 | 45,031.00 |
| Sep 30, 2023 | 45,970.00 |
| Sep 30, 2023 | 45,970.00 |